Therapeutic Options and Prognostic Factors in Treatment of Anaplastic Gliomas

Author:

Peulic Miodrag12,Grujicic Danica34,Milicevic Mihailo34,Ilic Rosanda34,Jokovic Milos34,Petrovic Marko12,Milosavljevic Aleksandar12

Affiliation:

1. University Clinical center of Kragujevac , Center for Neurosurgery, Kragujevac , Serbia

2. University of Kragujevac , Faculty of Medical Sciences, Kragujevac , Serbia

3. University Clinical Center of Serbia , Neurosurgery Clinic , Belgrade , Serbia

4. Faculty of Medicine University of Belgrade

Abstract

Abstract Introduction/objective: Anaplastic gliomas compromise about 5.9% of primary CNS tumors. The main goal of the operation is the maximum removal of the tumor, reduction of the tumor mass and reduction of the increased intracranial pressure. Different pathohistological subtypes of anaplastic gliomas show significantly different prognosis depending on the applied oncological therapeutic protocol as well as the modality of the applied radiotherapy. Materials and methods: The study was designed as a retrospective, clinical observational study. The study included 34 participants who were diagnosed with anaplastic glioma in the followed time period. Survival rates were calculated based on the localization, modality of therapy and complications. Results: we concluded that 20,4% of anaplastic gliomas were formed by transformation from previously operated lower grade gliomas. The initial sign of the disease is the appearance of epileptic seizures. Anaplastic gliomas most oftenly occur in the frontal region, with a frequency of 47%. The incidence of anaplastic gliomas in the temporal lobe is 23,5%. The length of survival is in relation to the localization of tumor expansion(p<0.05). The overall survival in the group of anaplastic gliomas operated on in the Department of Neurooncology KCS in the follow-up period of five years is 52.9%. Conclusion: The application of different chemotherapy modalities is not significant predictor in the length of survival. The radical nature of the operation has significance in the length of patient survival, which confirms the conclusions of most of the conducted studies cited in oncology textbooks.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Reference21 articles.

1. 1. Roth, Christian Hartmann et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology 2016; 18(11), 1529–1537.

2. 2. Vincent T. DeVita Jr. MD, Theodore S. Lawrence PhD, MD, Steven A. Rosenberg MD, PhD: Principles & Practice of Oncology,10th edition, Wolters Kluwer Health, 2015.

3. 3. David N. Louis et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System.2016; 131:803–820.

4. 4. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-1996.10.1016/S0140-6736(11)61346-9

5. 5. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97(4): 1063-1071.10.1002/cncr.11120

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3